Prestige BioPharma Limited (KRX:950210)
South Korea · Delayed Price · Currency is KRW 12,400
-120 (-0.96%)
At close: Oct 24, 2025
Prestige BioPharma Revenue
In the fiscal year ending June 30, 2025, Prestige BioPharma had annual revenue of 14.33B KRW with 1,978.97% growth. Prestige BioPharma had revenue of 5.53B in the quarter ending June 30, 2025, a decrease of -4,131.01%.
Revenue
14.33B
Revenue Growth
+1,978.97%
P/S Ratio
10.40
Revenue / Employee
n/a
Employees
n/a
Market Cap
149.04B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 14.33B | 13.64B | 1,978.97% |
| Jun 30, 2024 | 689.08M | 527.23M | 325.77% |
| Jun 30, 2023 | 161.84M | - | - |
| Jun 30, 2022 | - | - | - |
| Jun 30, 2021 | - | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.03T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| SK Biopharmaceuticals | 620.28B |
| PharmaResearch | 449.81B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |